A single nucleotide polymorphism in the matrix metalloproteinase 2 promoter is closely associated with high risk of nasopharyngeal carcinoma in Cantonese from southern China

Jian-Yong Shao¹,²,5,7, Yun Cao¹,², Xiao-Ping Miao³, Ma-Yan Huang¹,², Ling Deng¹,², Jian-Jun Hao⁴, Xiao-Man Liang¹, Li-Fu Hu⁶, Ingemar Ernberg⁶, Dong-Xin Lin⁶ and Yi-Xin Zeng¹,⁷

Abstract

Matrix metalloproteinase 2 (MMP2) has been shown to play an important role in several steps of cancer development. The −1306C/T polymorphism of the MMP2 gene displays a strikingly lower promoter activity than the T allele, and the CC genotype in the MMP2 promoter has been reported to associate with the development of several cancers. To assess the contribution of the MMP2 −1306C/T polymorphism to the risk of nasopharyngeal carcinoma (NPC), we conducted a case-control study and analyzed MMP2 genotypes in 370 patients with NPC and 390 frequency-matched controls using real-time PCR-based TaqMan allele analysis. We found that subjects with the CC genotype had an increased risk (OR = 1.55, 95% CI = 1.05–2.27) of developing NPC compared to those with the CT or TT genotypes. Furthermore, we found that the risk of NPC was markedly increased in subjects who were smokers (OR = 15.04, 95% CI = 6.65–33.99), heavy smokers who smoked ≥20 pack-years (OR = 18.66, 95% CI = 7.67–45.38), or young (<60 years) at diagnosis (OR = 1.52, 95% CI = 1.01–2.29). Our results provide molecular epidemiological evidence that the MMP2 −1306C/T promoter polymorphism is associated with NPC risk, and this association is especially noteworthy in heavy smokers.

Key words Matrix metalloproteinase 2 gene, polymorphism, nasopharyngeal carcinoma, smoker, epidemiology

To date, 20 human matrix metalloproteinases (MMPs) have been identified. MMPs degrade a range of extracellular matrix proteins and are implicated in connective tissue destruction and remodeling associated with cancer invasion, metastasis, and cartilage destruction in arthritis [1-3]. Therefore, MMPs were initially believed to be primarily involved in tumor invasion, blood vessel penetration, and metastasis through breakdown of physical barriers [4-6]. Recent work has suggested that, in addition to the historically considered features of promoting invasion and metastasis, MMPs may also be important for multiple steps of cancer development [7-8].

Naturally occurring genetic polymorphisms have been shown to have allele-specific effects on transcription of the MMP gene promoters and to be associated with susceptibility to cancers [8-9].

The MMP2 gene, which maps to 16q13, is 17-kb long and has 13 exons varying in size from 110 to 901 bp and 12 introns ranging in size from 175 to 4350 bp. MMP-2 is secreted as a pro-enzyme whose cleavage leads to the production of a soluble active form. A
naturally occurring sequence variation in the human MMP2 gene promoter was reported [16], and this single nucleotide polymorphism (SNP) is a C/T transition at -1306 that disrupts an Sp1-type promoter site (CCACC box) and displays a strikingly lower promoter activity than does the T allele. The CC genotype in the MMP2 promoter has been reported to associate with the development of gastric cardia adenocarcinoma [17], lung cancer [18], esophageal cancer [19], and breast cancer [20,21].

Nasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers in southern China. Epstein-Barr virus infection, chromosomal alterations, genetic and environmental factors have been reported to be involved in NPC etiology [18-20]. The clinically significant characteristics of NPC include early metastasis to lymph nodes, local invasiveness, and frequent local recurrence after treatment [21]. We recently reported in a molecular epidemiological study that the MMP2 -1306CC genotype is associated with a several-fold increased risk of lung cancer alone or through interaction with smoking exposure [19]. In this retrospective case-control study, we examined the contribution of the -1306C/T polymorphism in the MMP2 gene on NPC risk in a large molecular epidemiological study of a southern Chinese population.

Materials and Methods

Patients and samples

A total of 370 patients with NPC and 390 healthy controls, all ethnic Cantonese in southern China, were enrolled in this case-control study. All the patients with histopathologically confirmed NPC were untreated incident cases and were consecutively recruited between February 2000 and September 2003 at the Sun Yat-sen University Cancer Center. Disease staging was performed in accordance with the 1992 Chinese TNM staging classification [22]. Population controls were cancer-free individuals living in the Guangdong (Canton) region who were selected from a community cancer screening program for early cancer detection. The selection criteria included no individual history of cancer, and frequency matching to NPC cases was by age (±5 years), sex, smoking status, and ethnicity (Cantonese). However, because of the limited number of controls, we ultimately matched controls to NPC only by age and ethnicity (Cantonese). Overall, 385 eligible cases and 424 controls agreed to further risk factor interviews administered by a trained nurse interviewer, with the final study consisting of 370 cases (96% of eligible) and 390 controls (92% of eligible). Some subjects were excluded due to the failure of collecting blood samples from them. At recruitment, informed consent was obtained from each subject, and each participant was interviewed to solicit detailed information on demographic characteristics and lifetime history of tobacco use. Information was collected on the number of cigarettes smoked per day, the age at which the subjects started smoking, and the age at which ex-smokers stopped smoking. Smokers were considered to be current smokers if they smoked up to one year before the date of diagnosis for cases or up to the date of the interview for controls. The study included four ex-smokers, and all ex-smokers were in the light-smokers group. Because the number was so small, we recruited them into the current smokers group. This study was approved by the Hospital Review Board of the Sun Yat-sen University Cancer Center.

MMP2 genotyping

Genomic DNA was isolated from the peripheral blood of controls and NPC patients. Real-time polymerase chain reaction (PCR)-based TaqMan allele analysis was used to determine MMP2 genotypes. Primers amplifying a 63-bp fragment of the MMP2 promoter containing the -1306C/T site were MMP2-2F, 5'-AACATTCCCCATA-TTCCCCAC-3'; MMP2-2R, 5'-TTCTGACGTGAGACCT-GAAGAGC-3'; MMP2 -1306C genotype probe, 5'-VIC-AGCACTCCACCTT-MGB-3'; and MMP2 -1306T genotype probe, 5'-FAM-CAGCACTTACCTT-MGB-3'. TaqMan PCR was in a 25-μL reaction mixture containing 20 ng DNA, 1x TaqMan Master Mix (ABI, USA), 5 μL (0.9 μmol/L) of each primer, and 0.2 μmol/L FAM- or VIC-labeled probes. Reaction conditions were as follows: 10 min at 95°C, followed by 40 cycles of 15 s at 92°C and 1 min at 60°C. The MMP2 -1306C/T allele analysis was performed by using SDS software automatically on an Applied Biosystems 7900 System, and all patients and controls were genotyped twice.

Statistical analyses

Pearson’s chi-square test was used to examine differences in demographic variables, smoking status, and MMP2 -1306C/T polymorphism genotype distribution between patients and controls. Association between the MMP2 polymorphism and the risk of NPC was calculated by unconditional logistic regression models and estimated by odds ratios (ORs) and 95% confidence intervals (CIs). Light or heavy smokers were categorized by the 50th percentile pack-year value among controls, i.e., <20 or ≥20 pack-years (cigarettes per day × 20 × years smoked) [23]. ORs were adjusted for age, sex, and pack-years smoked. If combined risk was greater than the two independent risk factors, we considered the additive joint effects [24]. The Bonferroni correction was used for multiple comparisons. All
analyses were carried out with Statistical Analysis System software (version 6.12; SAS Institute, Cary, NC). A value of $P < 0.05$ was considered significant.

## Results

### Population characteristics

The distributions of age, sex, and smoking status of study subjects are shown in Table 1. No significant differences were observed between patients and controls in age distribution. The mean age was 46.3 years for the patient group and 43.0 years for the control group, and median age was 45 years for the patient group and 41 years for the control group. However, more smokers (including four ex-smokers) were present in the patient group than in the control group (68.7% vs. 28.5%, $P < 0.05$). The patient group included more males than did the control group ($P < 0.001$). Moreover, the distribution in light ($< 20$ pack-years) and heavy smokers ($\geq 20$ pack-years) between the patient and the control groups was significantly different ($P < 0.05$).

### MMP2 −1306C/T polymorphism and risk of NPC

Table 1. Characteristics of 370 nasopharyngeal carcinoma (NPC) patients and 390 control subjects

| Variable          | No. of patients (%) | No. of controls (%) | $P$  |
|-------------------|---------------------|---------------------|------|
| Gender            |                     |                     |      |
| Male              | 282 (76.2)          | 189 (48.5)          | <0.001 |
| Female            | 88 (23.8)           | 201 (51.5)          |      |
| Age (years)       |                     |                     | 0.53 |
| <60               | 315 (85.1)          | 343 (87.9)          |      |
| $\geq 60$         | 55 (14.9)           | 47 (12.1)           |      |
| Mean age $^*$     | 46.3 (12.1)         | 43.0 (16.0)         |      |
| Smoking status    |                     |                     | <0.001 |
| Non-smokers       | 116 (31.3)          | 279 (71.5)          |      |
| Smokers $^b$      | 254 (68.7)          | 111 (28.5)          | 0.002 |
| $<20$ pack-years  | 87 (23.5)           | 58 (14.9)           |      |
| $\geq 20$ pack-years | 167 (45.2) | 53 (13.6) |      |
| Mean pack-years smoked | 24.3 (14.3) | 23.7 (14.1) |      |
| Median pack-years smoked | 20 | 20 |      |

*The values in parentheses are standard deviation. $^b$Smokers included 4 ex-smokers.

Table 2. MMP2 genotypes in NPC patients and controls and its association with risk of NPC

| Genotype     | No. of patients | No. of controls | Adjusted OR (95% CI) $^*$ | $P$     |
|--------------|-----------------|-----------------|---------------------------|---------|
| CT + TT      | 59              | 84              | 1.00                      |         |
| CC           | 311             | 306             | 1.55 (1.05–2.27)          | 0.027   |
| T allele frequency | 0.08       | 0.11            |                           |         |

*Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression, with the MMP2 variant genotypes (CT + TT) as the reference group, and adjusted for age, sex, and smoking status.
risk was markedly increased in subjects who were light smokers (including four ex-smokers) (OR = 15.04, 95% CI = 6.65–33.99) and heavy smokers (OR = 18.66, 95% CI = 7.67–45.38). The ORs of single risk factors were 3.40 (95% CI = 2.63–4.40) for smokers, 2.78 (95% CI = 1.96–3.93) for light smokers, and 3.88 (95% CI = 2.87–5.24) for heavy smokers compared to non-smokers. Since the ORs for both smoking and the −1306CC genotype were greater than the sum minus 1 of the OR for smoking and the OR for the corresponding genotype, these data suggested more than additive joint effects between the genotype and smoking [24]. Thus, we observed more than additive joint effects between the MMP2 −1306CC genotype and smoking status.

MMP2–1306C/T polymorphism and clinical characteristics of NPC

The correlation between MMP2 genotype and NPC risk stratified by sex and age is given in Table 4. NPC risk associated with the CC genotype was significantly higher in subjects who were young (<60 years) at diagnosis (OR = 1.52, 95% CI = 1.01–2.29). The distribution of the CC genotype showed no significant difference between males and females (Table 4). The relationship between the −1306C/T polymorphism in the MMP2 gene promoter and risk of human malignancies has been documented. Populations carrying the MMP2 −1306CC genotype have increased risk of gastric cancer [20], lung cancer [13], esophageal carcinoma [20], colorectal cancer [20], and oral cancer [20]. In this investigation, our results revealed a significant difference in the distribution of the MMP2 allele variant CC in NPC patients and cancer-free controls. Subjects carrying the CC genotype had a 1.55-fold increased risk for NPC. In addition, we observed more than additive joint effects between this genetic polymorphism and cigarette smoking on increased risk of NPC, with an OR of 7.49 among light smokers and 18.66 among heavy smokers with the CC genotype. This study provides

### Table 3. Risk of NPC related to MMP2 genotypes and smoking status

| MMP2 genotype | Smoking status | No. of patients | No. of controls | Adjusted OR (95% CI) | P |
|---------------|----------------|----------------|----------------|----------------------|---|
| CT + TT       | Non-smokers    | 15             | 58             | 1.00                 |   |
|               | Smokers b      | 101            | 221            | 2.04 (1.06–3.96)     | 0.03 |
| CT + TT       | Smokers        | 46             | 26             | 5.79 (2.25–14.91)    | <0.001 |
| CC            | Pack-years <20 | 208            | 85             | 15.04 (6.65–33.99)   | <0.001 |
|               | Pack-years <20 | 11             | 11             | 2.81 (0.88–8.99)     | 0.06 |
|               | Pack-years >20 | 76             | 48             | 7.49 (3.16–17.78)    | <0.001 |
|               | Pack-years >20 | 35             | 15             | 8.04 (2.77–23.32)    | <0.001 |
|               | Pack-years >20 | 132            | 37             | 18.66 (7.67–45.38)   | <0.001 |

a ORs and 95% CIs were calculated by logistic regression, with the CT or TT genotype as the reference group, and adjusted for age and sex.
b Smokers included 4 ex-smokers.
c P value remained significant after Bonferroni correction.

### Table 4. Association between MMP2 polymorphisms and NPC risk stratified by sex and age

| Genotype | Male | Female |
|----------|------|--------|
|          | No. of patients | No. of controls | Adjusted OR (95% CI) | P |
|          | No. of patients | No. of controls | Adjusted OR (95% CI) | P |
| CT + TT  | 48   | 42     | 1.00 | 11 | 42 | 1.00 |
| CC       | 233  | 147    | 1.36 (0.86–2.17) | 0.15 | 78 | 159 | 1.41 (0.88–2.25) | 0.08 |

| Genotype | Age <60 years | Age ≥60 years |
|----------|---------------|---------------|
|          | No. of patients | No. of controls | Adjusted OR (95% CI) | P |
|          | No. of patients | No. of controls | Adjusted OR (95% CI) | P |
| CT + TT  | 58             | 80             | 1.00 | 5  | 8  | 1.00 |
| CC       | 257            | 263            | 1.52 (1.01–2.29) | 0.05 | 50 | 39 | 1.83 (0.50–6.68) | 0.36 |

a ORs and 95% CIs were calculated by logistic regression, with the MMP2 variant genotypes (CT + TT) as the reference group, and adjusted for age and smoking status; b ORs and 95% CIs were calculated by logistic regression, with the MMP2 variant genotypes (CT + TT) as the reference group, and adjusted for sex and smoking status.
substantial evidence that the MMP2–1306CC genotype, together with cigarette smoking, enhances NPC susceptibility and may be important for NPC development. Another study has reported that MMP2–1306CC is related to NPC risk in 239 patients in a Cantonese population (OR = 2.19, 95% CI = 1.21–3.96) [27]. Our results confirmed the susceptibility of MMP2–1306CC carriers to NPC in a larger population of 370 patients and further showed this susceptibility was more significant in subjects who were smokers, especially heavy smokers. In addition, we found that the risk of NPC was significantly increased in young (<60 years) subjects with the −1306CC genotype (OR = 1.52, 95% CI = 1.01–2.29). We also analyzed the relationship between −1306CC genotype and TNM stage but found no association between them.

The MMP2–1306C/T polymorphism impacts cellular function in vivo because the C→T transition at −1306 purportedly disrupts an Sp1-type promoter site (CCACC box), resulting in a strikingly lower promoter activity than does the T allele of the MMP2 gene [19]. The Sp1 site, with other promoter elements such as the AP-2 site, has been shown to be necessary for regulating constitutive expression of MMP2 [28]. Transient transfection experiments in vitro demonstrated that the Sp1 promoter site in the MMP2–1306C allele enhances the MMP2 transcription [19], indicating that MMP-2 protein expression would be higher in individuals with the CC genotype than in those with the TT or CT genotype. Since MMP-2 and other MMPs may contribute in multiple ways to all stages of carcinogenesis [8], the increased level of this enzyme over a lifetime may increase host susceptibility to cancer development. Experimental cancer models showed that mice lacking the MMP3, MMP1, or MMP9 genes developed fewer carcinogen-induced cancers than did wild-type mice [29], and transplanting MMP9-expressing bone marrow cells prevented development of squamous cell carcinomas in mice lacking the MMP9 [30]. MMP2-deficient mice were more susceptible to colonization by cancer cells injected in lung veins than wild-type mice [31], and overexpression of MMPs in transgenic mice resulted in elevated cancer susceptibility [15,32]. Similarly, our epidemiological study showed that the MMP2–1306CC genotype may result in high expression of MMP-2 over a lifetime and increase NPC susceptibility.

Cigarette smoking is a major cause of a variety of malignancies including cancers of the larynx, oral cavity and pharynx, esophagus, bladder, and lung. Numerous studies have consistently shown that cigarette smoking may be an important environmental etiological factor in NPC development in China [33,34]. In this study, we found a significantly higher risk for NPC related to the MMP2–1306CC genotype among smokers (including four ex-smokers) (OR = 15.04) and heavy smokers (OR = 18.66). Previous studies showed that cigarette smoking-induced NF-κB activation and NF-κB-regulated gene expression in human non-small cell lung carcinoma cells was suppressed by curcumin through inhibition of NF-κB kinase [35]. NF-κB activation blocks apoptosis, promotes proliferation, and mediates tumorigenesis. Cigarette smoking also induces 5-lipoxygenase (5-LOX) expression, which is important for activation of MMP-2 and vascular endothelial growth factor (VEGF), key proteins that induce angiogenic processes and promote inflammation-associated adenoma formation in mice [5,36]. We found that the association between the MMP2–1306CC genotype and

---

**Table 5. Risk of NPC related to MMP2 genotypes and TNM stage**

| Group | Numbera | Percentage (%) | Adjusted OR (95% CI)b | P |
|-------|---------|----------------|-----------------------|---|
| All cases | 311/370 | 84.1 | 1.55 (1.05–2.27) | 0.027 |
| T stage | | | | |
| T1 | 26/28 | 92.9 | 1.00 | |
| T2 + T3 + T4 | 285/342 | 83.3 | 0.61 (0.18–2.13) | 0.45 |
| N stage | | | | |
| N0 | 69/81 | 85.2 | 1.00 | |
| N1 + N2 + N3 | 242/289 | 83.7 | 0.97 (0.48–1.97) | 0.91 |
| M stage | | | | |
| M0 | 307/365 | 84.1 | 1.00 | |
| M1 | 4/5 | 80.0 | 0.93 (0.22–1.82) | 0.79 |
| TNM | | | | |
| I + II | 78/89 | 87.6 | 1.00 | |
| III + IV | 233/281 | 82.9 | 0.72 (0.35–1.49) | 0.35 |

a Number of patients with the CC genotype/total number of patients for each stratum.

b ORs and 95% CIs were calculated by logistic regression, with the CT or TT genotype as the reference group, and adjusted for age, sex, and smoking status.
NPC risk appeared to be more pronounced in young subjects (<60 years old). These results are consistent with the result of a previous study on gastric adenocarcinoma [13], which also supports the hypothesis that genetic susceptibility is often associated with an early age of disease onset. In summary, our investigation suggested that the MMP2 –1306CC genotype and the cigarette smoking environmental factor may cooperate in increasing NPC risk, especially in a young Cantonese population.

One explanation of these findings is that, in addition to higher constitutive expression from gaining an Sp1 promoter site, the smoking inducibility of the C allele of MMP2 may also be higher than the T allele, which lacks an Sp1 site. Given these conditions, smokers, especially heavy smokers, who carry the CC genotype are expected to be at the highest risk for developing NPC. Another explanation for a higher risk of NPC among smokers and heavy smokers with the CC genotype is that these subjects had larger numbers of transformed cells caused by tobacco carcinogens in the target tissue, consequently increasing the possibility that one of these cells will form a malignancy under the condition of higher MMP2 expression.

Although the design of the hospital-based case-control study has potential drawbacks such as selection bias, the results in this study are unlikely to be attributable to selection bias because of the large sample size that included >90% of all eligible cases, solid and reproducible genotyping procedures, and significantly increased ORs with very small P values. Genotype frequencies among the control population fit the Hardy-Weinberg law, further supporting the randomness of our control selection.

Local overexpression of MMP-2 is correlated with invasion and metastasis of certain cancers, including gastro-esophageal cancers. In this study, we found no significant association between MMP2 genotype and sex or TNM stage, suggesting that the CC genotype may not be a relevant genetic factor in inducing local overexpression of MMP-2. This study included only five cases with remote metastasis, and the smaller number of metastatic cases may have diminished the association between the MMP2 –1306CC genotype and TNM stage of NPC. Several studies reported that functional polymorphisms in other MMP genes including MMP1 (2G allele) and MMP3 (5A allele) are linked to susceptibility to certain human cancers [7,10]. Other reports and our results suggest that the MMP2 –1306C/T polymorphism might be a general, but not specific, risk factor for common cancers, further supporting the likelihood that MMPs profoundly influence early tumor initiation and development. However, the data on clinical outcomes should be considered preliminary because of our limited sample size. Additional examinations of larger patient series with more detailed clinicopathologic features and clinical outcome, especially survival rate, may be required.

Conclusions

In summary, our data provide molecular epidemiological evidence that the MMP2 –1306C/T promoter polymorphism is associated with NPC risk. In particular, our studies show that the CC genotype is associated with increased risk of NPC in the Cantonese population from southern China. This association is especially noteworthy in young individuals and heavy smokers. These findings further support the hypothesis that MMP2 is important in carcinogenesis and may ultimately help in identifying high-risk populations for NPC.

Acknowledgements

This work was supported in part by grants from the Chinese State Key Basic Research Project (No. 2011CB504805), National High Technology Research and Development Program of China (863 Program) (No. 20060102A4002), and a grant of 985 Project from Ministry of Education of P. R. China.

Received: 2010-12-23; revised: 2011-03-14; accepted: 2011-03-16.

References

[1] Ha HY, Moon HB, Nam MS, et al. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice [J]. Cancer Res, 2001,61(3):984–990.
[2] Masson R, Lefebvre O, Noel A, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy [J]. J Cell Biol, 1998,140 (6):1535–1541.
[3] Murray GI, Duncan ME, Arbuckle E, et al. Matrix metalloproteinases and their inhibitors in gastric cancer [J]. Gut, 1998,43(6):791–797.
[4] Brinkerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression [J]. Clin Cancer Res, 2000,6 (12):4823–4830.
[5] Franchi A, Santucci M, Masini E, et al. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix
metalloproteinase 9 in carcinoma of the head and neck [J]. Cancer, 2002;96(9):1902–1910.

[6] Vincenzi MP, Schroen DJ, Coon CI, et al. v-src activation of the collagenase-1 (matrix metalloproteinase-1) promoter through PE3A and STAT: requirement of extracellular signal-regulated kinases and inhibition by retinoic acid receptors [J]. Mol Carcinog, 1998;21(3):194–204.

[7] Zhu Y, Spitz MR, Lai L, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility [J]. Cancer Res, 2001,61(21):7825–7829.

[8] Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression [J]. Nat Rev Cancer, 2002;2(3):161–174.

[9] Kanamori J, Matsushita M, Minaguchi T, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region [J]. Cancer Res, 1999,59(17):4225–4227.

[10] Miao X, Yu C, Tan W, et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (−1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. [J]. Cancer Res, 2003,63(14):3987–3990.

[11] Yu C, Pan K, Xing D, et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer [J]. Cancer Res, 2002,62(22):6430–6433.

[12] Yu C, Zhou Y, Miao X, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer [J]. Cancer Res, 2004,64(20):7622–7628.

[13] Zhang J, Jin X, Fang S, et al. The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardia adenocarcinoma [J]. Cancerogenisis, 2004,25(12):2519–2524.

[14] Zinzindohoue F, Lecomte T, Ferraz JM, et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer [J]. Clin Cancer Res, 2005,11(2 Pt 1):594–599.

[15] Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of sp1 in allele-specific transcriptional regulation [J]. J Biol Chem, 2001,276(10):7549–7558.

[16] Grief F, Li WQ, Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype [J]. Breast Cancer Res Treat, 2004,88(3):197–204.

[17] Zhou Y, Yu C, Miao X, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes [J]. Carcinogenesis, 2004,25(3):399–404.

[18] Shao JY, Wang HY, Huang XM, et al. Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China [J]. Int J Oncol, 2000,17(6):1267–1275.

[19] Shao JY, Li YH, Gao HY, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma [J]. Cancer, 2004,100(6):1162–1170.

[20] Feng BJ, Huang W, Shugart YY, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4 [J]. Nat Genet, 2002,31(4):395–399.

[21] Chan AT, Teo ML, Lee WY, et al. The significance of keratinizing squamous cell histology in Chinese patients with nasopharyngeal carcinoma [J]. Clin Oncol (R Coll Radiol), 1998,10(3):161–164.

[22] Min H, Hong M, Ma J, et al. A new staging system for nasopharyngeal carcinoma in China [J]. Int J Radiat Oncol Biol Phys, 1994,30(5):1037–1042.

[23] Kleinbaum DG, Morganstein H, Kupper LL. Selection bias in epidemiologic studies [J]. Am J Epidemiol, 1981,113(4):452–463.

[24] Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? [J]. Carcinogenesis, 2002,23(3):381–387.

[25] Xu E, Lai M, Lv B, et al. A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer [J]. Biochem Biophys Res Commun, 2004,324(3):999–1003.

[26] Lin SC, Lo SS, Liu CJ, et al. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis [J]. J Oral Pathol Med, 2004,33(7):405–409.

[27] Zhou G, Zhai Y, Cui Y, et al. Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma [J]. Hum Mutat, 2007,28(11):1091–1097.

[28] Qin H, Sun Y. Berveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astrogliaoma cells [J]. J Biol Chem, 1999,274(41):29130–29137.

[29] Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J]. Nat Cell Biol, 2000,2(10):737–744.

[30] Coussens LM, Tickle CL, Hanahan D, et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis [J]. Cell, 2000,103(3):481–490.

[31] Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A–deficient mice [J]. Cancer Res, 1998,58(5):1048–1051.

[32] Sternlicht MD, Lochter A, Sympton CJ, et al. The stromal protein MMP3/stromelysin-1 promotes mammary carcinogenesis [J]. Cell, 1999,98(2):137–146.

[33] Yuan JM, Wang XL, Xiang YB, et al. Non-dietary risk factors for nasopharyngeal carcinoma in Shanghai, China [J]. Int J Cancer, 2000,85(3):364–369.

[34] Zhu K, Levine RS, Brann EA, et al. A population-based case-control study of the relationship between cigarette smoking and nasopharyngeal cancer (United States) [J]. Cancer Causes Control, 1996,6(6):507–512.

[35] Mercer BA, Kolesnikova N, Sonett J, et al. Extracellular regulated kinase/mitogen activated protein kinase is up-regulated in pulmonary emphysema and mediates matrix metalloproteinase-1 induction by cigarette smoke [J]. J Biol Chem, 2004,279(17):17690–17696.

[36] Galateau-Sallé FB, Luna RE, Horiba K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions [J]. Hum Pathol, 2000,31(3):296–305.